Funding sources: Some of the work described in this manuscript presents independent research funded by the National Institute for Health Research (NIHR) under the Programme Grants for Applied Research programme (the ‘RAPID’ project) (RP-PG-0707-10107) and the Central and East London NIHR Comprehensive Local Research Network. Professor Lyn S. Chitty is partially funded by the Great Ormond Street Hospital Children's Charity and the NIHR Biomedical Research Centre at Great Ormond Street Hospital. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
The clinical implementation of non-invasive prenatal diagnosis for single-gene disorders: challenges and progress made
Article first published online: 17 MAY 2013
© 2013 John Wiley & Sons, Ltd.
Special Issue: Noninvasive Prenatal Testing Using Maternal Plasma DNA: Part I
Volume 33, Issue 6, pages 555–562, June 2013
How to Cite
Lench, N., Barrett, A., Fielding, S., McKay, F., Hill, M., Jenkins, L., White, H. and Chitty, L. S. (2013), The clinical implementation of non-invasive prenatal diagnosis for single-gene disorders: challenges and progress made. Prenat. Diagn., 33: 555–562. doi: 10.1002/pd.4124
Conflicts of interest: None declared
- Issue published online: 17 MAY 2013
- Article first published online: 17 MAY 2013
- Accepted manuscript online: 16 APR 2013 08:39AM EST
Recently, we have witnessed the rapid translation into clinical practice of non-invasive prenatal testing for the common aneuploidies, most notably within the United States and China. This represents a lucrative market with testing being driven by companies developing and offering their services. These tests are currently aimed at women with high/medium-risk pregnancies identified by serum screening and/or ultrasound scanning. Uptake has been impressive, albeit limited to the commercial sector. However, non-invasive prenatal diagnosis (NIPD) for single-gene disorders has attracted less interest, no doubt because this represents a much smaller market opportunity and in the majority of cases has to be provided on a bespoke, patient or disease-specific basis. The methods and workflows are labour-intensive and not readily scalable. Nonetheless, there exists a significant need for NIPD of single-gene disorders, and the continuing advances in technology and data analysis should facilitate the expansion of the NIPD test repertoire. Here, we review the progress that has been made to date, the different methods and platform technologies, the technical challenges, and assess how new developments may be applied to extend testing to a wider range of genetic disorders. © 2013 John Wiley & Sons, Ltd.